Preserved supervised synthesis

Linaclotide synthesis · version 1

This URL preserves the exact reviewed public wording and source set for synthesis version 1.

Supervised synthesis

What do selected human studies report about Linaclotide?

Manually reviewed September 15, 2026 · version 1

Browse all Human Evidence Reviews · Open preserved synthesis version 1 →

Two publications report adult chronic-constipation trials and a pediatric functional-constipation trial. They do not cover the full irritable-bowel-syndrome program or every currently labeled age group.12

Bottom line from this bounded source set

Randomized trials reported improved bowel-movement measures over 12 weeks. Diarrhea is an important adverse effect; the pediatric trial included a serious dehydration event related to severe diarrhea.12

Reviewed study record

Adult chronic constipation: two trials

Design

Two randomized, double-blind, placebo-controlled 12-week trials tested two active groups.1

Population

1,276 adults with chronic constipation participated across the trials.1

Outcomes reported

The prespecified bowel-response endpoint was reached by approximately 16–21% of active-group participants versus 3–6% with placebo. Diarrhea led to discontinuation in 4.2% of active-group participants.1

Limitations

One publication contains two trials. Short follow-up cannot establish long-term benefit or uncommon harms, and the results do not automatically extend to other diagnoses or ages.1

Reviewed study record

Pediatric functional constipation

Design

Randomized, double-blind, placebo-controlled phase 3 trial lasting 12 weeks.2

Population

330 children aged 6–17 years were randomized; 328 received treatment and 293 completed.2

Outcomes reported

The adjusted between-group difference was 1.17 additional spontaneous bowel movements per week. Diarrhea occurred in seven of 164 active-group and three of 164 placebo participants; one active-group participant required hospitalization for dehydration.2

Limitations

The trial addresses functional constipation in the enrolled age range. Its findings cannot establish safety in younger children or replace age-specific label warnings.2

Reviewed source set

  1. PubMed · 21830967Two randomized trials of linaclotide for chronic constipation. ↗PubMed PMID 21830967 · EFetch XML reviewed 2026-09-15 · payload SHA-256 24d773849646882ab3031eef6fc3481ce604a26f409a13a58e22a2004aca0a3b
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1056/nejmoa1010863. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  2. PubMed · 38211604Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. ↗PubMed PMID 38211604 · EFetch XML reviewed 2026-09-15 · payload SHA-256 58b2d55045c664eb19aec9f97374ea3268f561017615f37584eb189d4c41c982
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/s2468-1253(23)00398-9. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗